博瑞医药
(688166)
| 流通市值：224.07亿 | | | 总市值：224.07亿 |
| 流通股本：4.23亿 | | | 总股本：4.23亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 248,959,843.43 | 1,282,551,614.5 | 976,825,695.67 | 657,688,446.99 |
| 营业收入 | 248,959,843.43 | 1,282,551,614.5 | 976,825,695.67 | 657,688,446.99 |
| 二、营业总成本 | 266,560,026.02 | 1,102,598,723.72 | 798,339,394.77 | 554,212,734.85 |
| 营业成本 | 139,552,951.79 | 544,950,815.79 | 410,241,469.76 | 294,016,999.7 |
| 税金及附加 | 2,686,271.42 | 8,419,669.89 | 5,066,165.95 | 3,149,122.03 |
| 销售费用 | 17,425,476.55 | 71,743,054.11 | 56,240,619.67 | 39,640,646.11 |
| 管理费用 | 34,507,017.62 | 139,123,381.53 | 84,725,762.7 | 55,778,382.34 |
| 研发费用 | 61,638,706.67 | 297,452,702.27 | 212,379,034.01 | 142,763,374.89 |
| 财务费用 | 10,749,601.97 | 40,909,100.13 | 29,686,342.68 | 18,864,209.78 |
| 其中:利息费用 | 14,972,467.48 | 52,435,026.77 | 39,583,215.14 | 27,568,677.41 |
| 其中:利息收入 | 1,141,673.27 | 10,963,526.58 | 8,787,032.44 | 7,014,494.12 |
| 加:公允价值变动收益 | 1,722,160.93 | -5,699,782.83 | 1,009,679.56 | -1,564,027.29 |
| 加:投资收益 | -1,112,645.51 | -11,633,803.45 | -9,634,825.62 | -6,584,076.76 |
| 资产减值损失(新) | 708,012.2 | -19,942,512.38 | -5,233,377.22 | -5,233,377.22 |
| 信用减值损失(新) | -3,203,261.81 | -12,353,172.29 | -7,251,559.45 | -4,417,727.49 |
| 其他收益 | 7,589,558.61 | 29,965,430.1 | 10,974,695.35 | 8,720,734.45 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -11,896,358.17 | 160,289,049.93 | 168,350,913.52 | 94,397,237.83 |
| 加:营业外收入 | 99,446.12 | 48,309.78 | 35,088.06 | 28,588.06 |
| 减:营业外支出 | 66,966.84 | 3,136,751.31 | 309,658.44 | 119,565.61 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -11,863,878.89 | 157,200,608.4 | 168,076,343.14 | 94,306,260.28 |
| 减:所得税费用 | -7,207,107.71 | 15,937,323.86 | 21,318,816.3 | 12,079,271.64 |
| 六、净利润 | -4,656,771.18 | 141,263,284.54 | 146,757,526.84 | 82,226,988.64 |
| 持续经营净利润 | -4,656,771.18 | 141,263,284.54 | 146,757,526.84 | 82,226,988.64 |
| 归属于母公司股东的净利润 | 12,959,776.09 | 189,166,937.36 | 177,408,752.96 | 106,364,734.26 |
| 少数股东损益 | -17,616,547.27 | -47,903,652.82 | -30,651,226.12 | -24,137,745.62 |
| (一)基本每股收益 | 0.03 | 0.45 | 0.42 | 0.25 |
| (二)稀释每股收益 | 0.03 | 0.45 | 0.42 | 0.25 |
| 八、其他综合收益 | -70,221.14 | -37,833,359.39 | -35,070,709.12 | -35,136,666.18 |
| 归属于母公司股东的其他综合收益 | -70,221.14 | -37,833,359.39 | -35,070,709.12 | -35,136,666.18 |
| 九、综合收益总额 | -4,726,992.32 | 103,429,925.15 | 111,686,817.72 | 47,090,322.46 |
| 归属于母公司股东的综合收益总额 | 12,889,554.95 | 151,333,577.97 | 142,338,043.84 | 71,228,068.08 |
| 归属于少数股东的综合收益总额 | -17,616,547.27 | -47,903,652.82 | -30,651,226.12 | -24,137,745.62 |
| 公告日期 | 2025-04-18 | 2025-04-03 | 2024-10-30 | 2024-08-24 |
| 审计意见(境内) | | 标准无保留意见 | | |